HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antihelicase action of CI-958, a new drug for prostate cancer.

Abstract
CI-958, a new DNA-intercalating drug derived from a series of substituted 2H-[1] benzothiopyrano[4,3,2-cd]indazoles, is being tested in clinical trails because of its curative properties against murine solid tumor models and because it has demonstrated activity in a pilot phase II study of patients with hormone-refractory prostate cancer. However, the mechanism of anticancer action of CI-958 has not been established. Because CI-958 binds to DNA and DNA helicases are profoundly affected by DNA-binding drugs, we examined the effects of CI-958 on human DNA helicase action. DNA helicase activity was measured by strand dissociation of double-stranded (ds) DNA with a gel electrophoresis assay, and ATPase activities were determined on thin-layer chromatography by measurement of the conversion of ATP to ADP. For human helicase blockade, CI-958 is slightly more potent than doxorubicin (EC50 values 0.17 and 0.26 microM, respectively). We observed no difference in helicase-blockade EC50 values recorded for three helicase substrates containing A-T rich, G-C rich, and both types of oligonucleotide sequences. The effects of CI-958 helicase blockade and DNA-dependent ATPase activities were similar for the two reactions. The kinetics of the blockade by CI-958 of the human DNA helicase indicates that it involves a reversible ternary complex of helicase-drug-dsDNA. CI-958 produces potent blockade of human DNA helicases with no apparent strong DNA sequence-binding preference. Similar potency against helicase strand dissociation and DNA-dependent ATPase suggests that the mechanism against these reactions is the same. The blockade of DNA helicases by CI-958 may be central in its mechanism of action as an anticancer drug.
AuthorsL Lun, P M Sun, C M Trubey, N R Bachur
JournalCancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 42 Issue 6 Pg. 447-53 ( 1998) ISSN: 0344-5704 [Print] Germany
PMID9788570 (Publication Type: Journal Article)
Chemical References
  • Antineoplastic Agents
  • DNA Primers
  • Enzyme Inhibitors
  • Indazoles
  • ledoxantrone
  • DNA Helicases
Topics
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Base Sequence
  • DNA Helicases (antagonists & inhibitors)
  • DNA Primers
  • Enzyme Inhibitors (pharmacology, therapeutic use)
  • Humans
  • Indazoles (pharmacology, therapeutic use)
  • Kinetics
  • Male
  • Prostatic Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: